Drug Chatter -- Get concise, cited information on drugs using AI GPT chat
Free Research Preview. DrugChatter may produce inaccurate information.

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Fda pediatric exclusivity 6 months extension all drugs?

See the DrugPatentWatch profile for pediatric

What is the FDA pediatric exclusivity 6-month extension?

The FDA can extend the marketing exclusivity for certain drugs by 6 months to encourage pediatric studies. This extension is tied to the sponsor submitting required pediatric assessments under FDA’s Written Request process. The pediatric exclusivity extension can apply even when the drug already has other exclusivity types, as long as it meets the program rules. [1]

Does it apply to all drugs?

No. Pediatric exclusivity is not automatic for “all drugs.” It generally applies only to eligible products with qualifying exclusivity that can be extended and that have met the pediatric study requirements under FDA’s pediatric exclusivity framework. [1]

Which types of FDA exclusivity can get the 6-month pediatric extension?

Pediatric exclusivity is designed to extend certain existing marketing exclusivities (the 6-month add-on relates to the drug’s exclusivity term rather than regulatory approval itself). The exact eligibility depends on the type of exclusivity and whether the sponsor’s pediatric submission satisfies FDA’s Written Request requirements. [1]

How do companies qualify for the 6-month pediatric exclusivity?

Sponsors must submit pediatric information that corresponds to an FDA-issued Written Request for pediatric studies. If the request is fulfilled, the pediatric exclusivity extension may be granted, extending the relevant exclusivity by 6 months. [1]

How long does pediatric exclusivity extend the original exclusivity term?

The extension is 6 months, added to the existing marketing exclusivity period for the eligible drug, based on FDA’s pediatric exclusivity determination. [1]

Why do people say “not all drugs” and what are common edge cases?

People often summarize pediatric exclusivity as a blanket rule, but in practice eligibility depends on whether:
- the drug has an exclusivity term that can be extended under the program, and
- the sponsor fulfills the FDA Written Request with the required pediatric studies/submissions. [1]

Where can I verify if a specific drug got the pediatric exclusivity extension?

You can verify for a particular product through FDA’s pediatric exclusivity listings and related FDA materials tied to that drug’s exclusivity status. [1]

Sources:
1. FDA (Pediatric Exclusivity): https://www.fda.gov/drugs/development-resources/pediatric-exclusivity



Other Questions About Pediatric :

Fda pediatric exclusivity granted 2020? Fda pediatric exclusivity granted 2022? Fda pediatric exclusivity granted 2020 2021 2022 2023 2024 complete list? Fda pediatric exclusivity 6 months? Fda pediatric exclusivity determinations 2020 2021 2022 2023 2024? Pediatric aspirin dosage? Fda pediatric exclusivity determinations 2024?

AI-Drug Label Prescribing Information Alignment Report

35
35%
Grade D

Poor

Not Aligned

Patient Risk: Low

Summary

Most claims concern FDA pediatric exclusivity/marketing exclusivity extensions, which are not addressed in the INFUVITE PEDIATRIC prescribing information excerpts provided. No AI statements were verifiable against the supplied label content.


Category Scores

Indication
0
Poor
Indication
0
Poor

Accurate Statements


Unsupported Statements

The FDA can extend the marketing exclusivity for certain drugs by 6 months to encourage pediatric studies.
Not supported by the provided INFUVITE PEDIATRIC prescribing information excerpts; label content supplied does not discuss marketing/pediatric exclusivity extensions.
The 6-month pediatric exclusivity extension is tied to the sponsor submitting required pediatric assessments under the FDA Written Request process.
Not supported by the provided INFUVITE PEDIATRIC prescribing information excerpts.
The pediatric exclusivity extension can apply even when the drug already has other exclusivity types, as long as it meets the program rules.
Not supported by the provided INFUVITE PEDIATRIC prescribing information excerpts.
Pediatric exclusivity is not automatic for all drugs.
Not supported by the provided INFUVITE PEDIATRIC prescribing information excerpts.
Pediatric exclusivity generally applies only to eligible products with qualifying exclusivity that can be extended.
Not supported by the provided INFUVITE PEDIATRIC prescribing information excerpts.
Eligible products must have met the pediatric study requirements under FDA’s pediatric exclusivity framework.
Not supported by the provided INFUVITE PEDIATRIC prescribing information excerpts.
Pediatric exclusivity extends certain existing marketing exclusivities.
Not supported by the provided INFUVITE PEDIATRIC prescribing information excerpts.
The pediatric exclusivity 6-month add-on relates to the drug’s exclusivity term rather than regulatory approval itself.
Not supported by the provided INFUVITE PEDIATRIC prescribing information excerpts.
Eligibility for the 6-month pediatric extension depends on the type of exclusivity and whether the sponsor’s pediatric submission satisfies FDA’s Written Request requirements.
Not supported by the provided INFUVITE PEDIATRIC prescribing information excerpts.
Sponsors must submit pediatric information that corresponds to an FDA-issued Written Request for pediatric studies.
Not supported by the provided INFUVITE PEDIATRIC prescribing information excerpts.
If the Written Request is fulfilled, the pediatric exclusivity extension may be granted.
Not supported by the provided INFUVITE PEDIATRIC prescribing information excerpts.
The pediatric exclusivity extension extends the relevant exclusivity by 6 months.
Not supported by the provided INFUVITE PEDIATRIC prescribing information excerpts.
The extension is 6 months added to the existing marketing exclusivity period for the eligible drug based on FDA’s pediatric exclusivity determination.
Not supported by the provided INFUVITE PEDIATRIC prescribing information excerpts.
Eligibility depends on whether the drug has an exclusivity term that can be extended under the program.
Not supported by the provided INFUVITE PEDIATRIC prescribing information excerpts.
Eligibility depends on whether the sponsor fulfills the FDA Written Request with the required pediatric studies/submissions.
Not supported by the provided INFUVITE PEDIATRIC prescribing information excerpts.
A specific drug’s pediatric exclusivity extension can be verified through FDA’s pediatric exclusivity listings and related FDA materials tied to that drug’s exclusivity status.
Not supported by the provided INFUVITE PEDIATRIC prescribing information excerpts.

Contradictions


Important Omissions

INFUVITE PEDIATRIC-specific prescribing information claims relevant to the audit context (e.g., indication wording, dosing/administration instructions, contraindications, warnings/precautions, drug interactions, adverse reactions) were not addressed in the AI statements provided.
Importance: Moderate

Safety Assessment

Potential Patient Risk: Low
The provided AI statements do not describe patient dosing, contraindications, or clinical safety risks for INFUVITE PEDIATRIC; however, they are largely unrelated to the supplied product label content.

Regulatory Assessment

On Label No
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk High

Recommendation

Not Aligned

Primary Issue
Claims focus on FDA pediatric exclusivity/marketing exclusivity mechanisms, which are not contained in the provided INFUVITE PEDIATRIC prescribing information excerpts.

Suggested Improvement
Limit statements to what is present in the INFUVITE PEDIATRIC label excerpts (e.g., indication for prevention of vitamin deficiency in pediatric patients up to 11 years receiving parenteral nutrition; administration/dilution and key warnings/precautions/interactions) or provide the correct label section/source that addresses exclusivity and Written Request mechanisms.

Drug Brand Mention Assessment

Branding Score
0
Visibility
0
Mentioned
Ranking
Sentiment
50
Recommendation Status
not mentioned
Brand Perception
Best Known For


Core Claims
Differentiators

Pricing Perception: Not Mentioned